3
Announcements
Trials
Browse
Landscape
Sponsor
Conditions
Glioblastoma
12
Prostatic Neoplasms
11
Oropharyngeal Neoplasms
10
Lung Neoplasms
10
Carcinoma, Non-Small-Cell Lung
10
Breast Neoplasms
9
Glioma
8
Urinary Bladder Neoplasms
7
Squamous Cell Carcinoma of Head and Neck
6
Esophageal Neoplasms
6
Neoplasm Metastasis
5
Mouth Neoplasms
5
Carcinoma
5
Burkitt Lymphoma
5
Astrocytoma
5
Sarcoma
4
Pancreatic Neoplasms
4
Laryngeal Neoplasms
4
Gliosarcoma
4
Carcinoma, Hepatocellular
4
Brain Neoplasms
4
Adenocarcinoma of Lung
4
Adenocarcinoma Of Esophagus
4
Uterine Cervical Neoplasms
3
Triple Negative Breast Neoplasms
3
Stomach Neoplasms
3
Rhabdomyosarcoma, Embryonal
3
Rhabdomyosarcoma
3
Rectal Neoplasms
3
Neoplasms
3
Interventions
lutetium Lu 177 dotatate
12
Specimen Handling
6
Magnetic Resonance Spectroscopy
6
cabozantinib
5
Everolimus
5
pembrolizumab
4
Nivolumab
4
olaparib
3
lenvatinib
3
Cyclophosphamide
3
177Lu-octreotide, DOTA(0)-Tyr(3)-
3
lanreotide
2
gallium Ga 68 dotatate
2
fludarabine phosphate
2
fludarabine
2
avelumab
2
amino-acid, glucose, and electrolyte solution
2
X-Rays
2
Phantoms, Imaging
2
Octreotide
2
Lutetium-177
2
Ipilimumab
2
3-aminopyridine-2-carboxaldehyde thiosemicarbazone
2
tivozanib
1
surufatinib
1
repotrectinib
1
peposertib
1
pazopanib
1
entrectinib
1
belinostat
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
0 trials
Recent
Start date
Enrollment
Neuroendocrine Tumors
×
Radiation
×
90 days
×
Clear all
No trials found.